| Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. | |
| | |
MedLine Citation:
|
PMID: 18158956 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The treatment of steroid-refractory acute graft-versus-host disease (aGVHD) remains a clinical challenge, for which no standard therapy exists. Alemtuzumab is a humanized anti-CD52 monoclonal antibody (mAb) that has been successfully used as part of conditioning regimens for hematopoietic stem cell transplantation (HSCT) to prevent GVHD. The purpose of this study was to evaluate the safety and efficacy of alemtuzumab in treating steroid-refractory aGVHD (>or=grade II) following HSCT. Eighteen patients received subcutaneous alemtuzumab 10 mg daily on 5 consecutive days. Response was assessed at day 28 following initiation of alemtuzumab. Eight patients had grade II aGVHD, 8 had grade III, and 2 had grade IV. The main organ involved was the liver in 4 patients, gastrointestinal (GI) tract in 5, skin in 3, skin and liver in 3, and skin and GI tract in 3. Fifteen patients (83%) responded to alemtuzumab, including 6 (33%) with complete response. All 3 unresponsive patients died of GVHD. Ten of 15 responders are alive at median follow-up of 11 months (range: 3-24). Infections occurred in 14 patients, including cytomegalovirus (CMV) reactivation in 11. Grade 3 neutropenia and thrombocytopenia occurred in 6 and 4 patients, respectively. Alemtuzumab was well tolerated, and induces promising response rates in steroid-refractory aGVHD. |
| | |
Authors:
|
David Gómez-Almaguer; Guillermo J Ruiz-Argüelles; Luz del Carmen Tarín-Arzaga; Oscar González-Llano; Homero Gutiérrez-Aguirre; Olga Cantú-Rodríguez; José Jaime-Pérez; Antonio Carrasco-Yalán; Sergio Giralt |
Related Documents
:
|
16704436 - Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relap... 16842526 - Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: ... 7773166 - Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. 14607756 - Long-term disease-free survival in patients with angioimmunoblastic t-cell lymphoma aft... 17158776 - When can a second conservative approach be considered for ipsilateral breast tumour rec... 8680126 - Successful treatment of bronchial mucoepidermoid carcinoma in an 11-year-old boy by bro... |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Volume: 14 ISSN: 1523-6536 ISO Abbreviation: Biol. Blood Marrow Transplant. Publication Date: 2008 Jan |
Date Detail:
|
Created Date: 2007-12-26 Completed Date: 2008-01-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9600628 Medline TA: Biol Blood Marrow Transplant Country: United States |
Other Details:
|
Languages: eng Pagination: 10-5 Citation Subset: IM |
Affiliation:
|
Servicio de Hematología, Hospital Universitario Dr. José E. González, Universidad Autónoma Nuevo León, Monterrey, NL, México. dr_gomez@infosel.net.mx |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adrenal Cortex Hormones / adverse effects Adult Antibodies, Monoclonal / adverse effects, therapeutic use* Antibodies, Neoplasm / adverse effects, therapeutic use* Antigens, CD / immunology* Antigens, Neoplasm / immunology* Child Child, Preschool Female Glycoproteins / immunology* Graft vs Host Disease / drug therapy* Hematopoietic Stem Cell Transplantation / adverse effects* Humans Infant Injections, Subcutaneous Kaplan-Meiers Estimate Male Middle Aged Transplantation, Homologous / adverse effects Treatment Failure |
| Chemical | |
Reg. No./Substance:
|
0/Adrenal Cortex Hormones; 0/Antibodies, Monoclonal; 0/Antibodies, Neoplasm; 0/Antigens, CD; 0/Antigens, Neoplasm; 0/CD52 antigen; 0/Glycoproteins; 0/alemtuzumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease.
Next Document: Importance of interleukin-7 in the development of experimental graft-versus-host disease.